WINTEAM PHARMA
WINTEAM PHARMA operates in Diversified Metals & Mining.
WINTEAM PHARMA (WSG) - Total Assets
Latest total assets as of December 2023: €37.07 Billion EUR
Based on the latest financial reports, WINTEAM PHARMA (WSG) holds total assets worth €37.07 Billion EUR as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
WINTEAM PHARMA - Total Assets Trend (2016–2023)
This chart illustrates how WINTEAM PHARMA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
WINTEAM PHARMA - Asset Composition Analysis
Current Asset Composition (December 2023)
WINTEAM PHARMA's total assets of €37.07 Billion consist of 53.4% current assets and 46.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.1% |
| Accounts Receivable | €9.69 Billion | 26.1% |
| Inventory | €5.96 Billion | 16.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €5.49 Billion | 14.8% |
| Goodwill | €3.46 Billion | 9.3% |
Asset Composition Trend (2016–2023)
This chart illustrates how WINTEAM PHARMA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: WINTEAM PHARMA's current assets represent 53.4% of total assets in 2023, an increase from 38.4% in 2016.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2023, down from 10.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, a decrease from 48.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 26.1% of total assets.
WINTEAM PHARMA Competitors by Total Assets
Key competitors of WINTEAM PHARMA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
XIWANG SPECIAL STEE (2XI.SG)
STU:2XI
|
Germany | €15.07 Billion |
|
LINDT & SPRUENGLI N - Dusseldorf Stock Exchang
DU:LSPN
|
Germany | €7.86 Billion |
|
PRICELINE.COM
BE:PCE1
|
Germany | €27.98 Billion |
|
PRICELINE GROUP (PCE1.SG)
STU:PCE1
|
Germany | €27.98 Billion |
|
MURPHY USA
BE:1MU
|
Germany | €4.40 Billion |
|
RESMED (RME.SG)
STU:RME
|
Germany | €7.22 Billion |
|
DIOS EXPLORATIONS
BE:BFM
|
Germany | €7.25 Million |
|
CHINA YUCHAI INTL (CYD.SG)
STU:CYD
|
Germany | €25.76 Billion |
WINTEAM PHARMA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - WINTEAM PHARMA generates 0.49x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, WINTEAM PHARMA generates $ 3.47 in net profit.
WINTEAM PHARMA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.12 | 1.78 | 1.38 |
| Quick Ratio | 1.48 | 1.18 | 0.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €10.47 Billion | € 7.86 Billion | € 4.18 Billion |
WINTEAM PHARMA - Advanced Valuation Insights
This section examines the relationship between WINTEAM PHARMA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | €37.07 Billion |
| Market Capitalization | $2.23K USD |
Valuation Analysis
Below Book Valuation: The market values WINTEAM PHARMA's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: WINTEAM PHARMA's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for WINTEAM PHARMA (2016–2023)
The table below shows the annual total assets of WINTEAM PHARMA from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €37.07 Billion | +4.02% |
| 2022-12-31 | €35.64 Billion | -2.12% |
| 2021-12-31 | €36.41 Billion | +10.04% |
| 2020-12-31 | €33.09 Billion | +1.89% |
| 2019-12-31 | €32.47 Billion | +7.22% |
| 2018-12-31 | €30.29 Billion | +21.71% |
| 2017-12-31 | €24.89 Billion | +18.29% |
| 2016-12-31 | €21.04 Billion | -- |